Login/Register

News

GlycoNex and UK’s Sterling Sign Manufacturing Agreement for GNX102-ADC

On the 12th, GlycoNex announced that it has signed a manufacturing agreement with UK-based contract development and manufacturing organization Sterling Pharma Solutions. Under this agreement, Sterling’s specialized Antibody-Drug Conjugate (ADC) division will manufacture GlycoNex’s GNX102-ADC in preparation for its upcoming Phase I human clinical trial.

Read more
Nov 13, 2024
Nov 13, 2024
Nov 13, 2024
Nov 13, 2024
Nov 13, 2024
Nov 12, 2024
Nov 12, 2024
Nov 12, 2024
Nov 12, 2024